Two new medicines for type 2 diabetes
Two new medicines for type 2 diabetes will be funded, from 1 October 2018. Through an agreement with Novartis New Zealand Limited (Novartis).
- Vildagliptin (Galvus) for type 2 diabetes mellitus
- Vildagliptin with metformin (Galvumet) for type 2 diabetes mellitus
It is excellent that Pharmac are funding Vildagliptin, a new class of medication for diabetes.
However, there are other classes of medication that have more proven health benefits than Vildagliptin. We feel that our population of people with diabetes should be funded for a variety of the new classes of medication that offers them best health outcomes according to international evidence and guidelines.
Pharmac's press release and more detail here